Tuberc Respir Dis.  1982 Dec;29(4):183-188. 10.4046/trd.1982.29.4.183.

Follow-up Study of Short-Course Chemotherapy for Pulmonary Tuberculosis

• KMID: 2528816
• DOI: http://doi.org/10.4046/trd.1982.29.4.183

Abstract

A clinical study was done on 381 pulmonary tuberculosis patients treated with streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ). Out of 381 patients, 197(51. 7%) have completed the prescribed duration or more of the treatment and 184 patients(48. 3%) have dropped out due to various reasons. Among 197 patients who have completed the chemotherapy, 82 patients have been treated beyond the 9 months treatment due to mainly drug resistance and retreatment. The most common cause of premature interruption was drop-out against advice. One hundred twelve patients have been followed up for more than 6 months after the termination of chemotherapy, and 86 were followed up for more than twelve months. There ￦ere no relapse at all. Among 279 patients who have been on treatment for more than one month, 58 patients (20.9%) experienced adverse reactions: 22(7.9%) changed the regimen; others unchanged. The most frequent adverse reaction was hepatotoxicity. In conclusion, SHRZ for 9 month was very effective, however, change of regimen might be necessary in case of side effect or drug-resistant case.